125 related articles for article (PubMed ID: 30160395)
21. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
[TBL] [Abstract][Full Text] [Related]
22. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
23. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
24. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care.
Killilea T
Am J Manag Care; 2002 Oct; 8(16 Suppl):S441-9. PubMed ID: 12408407
[TBL] [Abstract][Full Text] [Related]
25. Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease.
Gao Y; Peterson E; Pagidipati N
Clin Cardiol; 2019 Nov; 42(11):1063-1070. PubMed ID: 31448852
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
28. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Skra J; Valensi P; Ceriello A
Cardiovasc Diabetol; 2016 Feb; 15():33. PubMed ID: 26892706
[TBL] [Abstract][Full Text] [Related]
29. Clinical and Economic Impact of a Digital, Remotely-Delivered Intensive Behavioral Counseling Program on Medicare Beneficiaries at Risk for Diabetes and Cardiovascular Disease.
Chen F; Su W; Becker SH; Payne M; Castro Sweet CM; Peters AL; Dall TM
PLoS One; 2016; 11(10):e0163627. PubMed ID: 27706216
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a
Cefalu WT; Kaul S; Gerstein HC; Holman RR; Zinman B; Skyler JS; Green JB; Buse JB; Inzucchi SE; Leiter LA; Raz I; Rosenstock J; Riddle MC
Diabetes Care; 2018 Jan; 41(1):14-31. PubMed ID: 29263194
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden.
Quilici S; Chancellor J; Maclaine G; McGuire A; Andersson D; Chiasson JL
Int J Clin Pract; 2005 Oct; 59(10):1143-52. PubMed ID: 16178980
[TBL] [Abstract][Full Text] [Related]
32. Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison.
Shimazawa R; Ikeda M
Br J Clin Pharmacol; 2021 Oct; 87(10):3938-3948. PubMed ID: 33704809
[TBL] [Abstract][Full Text] [Related]
33. Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
Ou HT; Chen YT; Liu YM; Wu JS
Diabetes Res Clin Pract; 2016 Jun; 116():14-25. PubMed ID: 27321311
[TBL] [Abstract][Full Text] [Related]
34. Predictors of government subsidized pharmaceutical use in patients with diabetes or cardiovascular disease in a primary care setting: evidence from a prospective randomized trial.
Hirst NG; Whitty JA; Synnott RL; Eley DS; Scuffham PA
J Med Econ; 2011; 14(6):698-704. PubMed ID: 21892854
[TBL] [Abstract][Full Text] [Related]
35. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Nguyen E; Coleman CI; Nair S; Weeda ER
J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.
Sun X; Guo L; Shang H; Ren M; Wang Y; Huo D; Lei X; Wang H; Zhai J
Trials; 2015 Nov; 16():496. PubMed ID: 26530718
[TBL] [Abstract][Full Text] [Related]
38. Diabetes pharmacy management: balancing safety, cost, and outcomes.
Dunn JD
Am J Manag Care; 2010 Aug; 16(7 Suppl):S201-6. PubMed ID: 20809669
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
40. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes.
Mody R; Kalsekar I; Kavookjian J; Iyer S; Rajagopalan R; Pawar V
J Diabetes Complications; 2007; 21(2):75-83. PubMed ID: 17331855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
